BMS-345541 Hydrochloride: Selective IKK/NF-κB Pathway Inhibitor for Inflammation and Cancer Research

Executive Summary: BMS-345541 hydrochloride is a potent and selective inhibitor of IκB kinase isoforms IKK-1 and IKK-2, with IC₅₀ values of 4 μM and 0.3 μM, respectively, under cell-free assay conditions (APExBIO). It operates by binding to an allosteric site on IKK, blocking downstream NF-κB-dependent transcription of pro-inflammatory cytokines such as TNFα, IL-1β, IL-6, and IL-8 (Zhao et al., 2025). The compound demonstrates high specificity, not inhibiting other serine/threonine or tyrosine kinases (see advanced mechanistic review). It induces apoptosis and G2/M cell cycle arrest in T-cell acute lymphoblastic leukemia (T-ALL) models (mechanistic insights). BMS-345541 hydrochloride is water-soluble at ≥60 mg/mL and is recommended for storage at -20°C for several months; long-term solution storage is discouraged (APExBIO).

Biological Rationale

NF-κB is a transcription factor central to immune and inflammatory responses. Aberrant activation of the IKK/NF-κB pathway is implicated in chronic inflammation, cancer, and chemoresistance (Zhao et al., 2025). In diseases such as T-cell acute lymphoblastic leukemia (T-ALL), NF-κB-driven gene expression sustains cell survival and proliferation. Targeting IκB kinase (IKK) disrupts this pathway, providing a targeted approach to modulate excessive inflammation and tumor cell growth. BMS-345541 hydrochloride is designed to selectively inhibit IKK-1 and IKK-2, making it an optimal tool for dissecting and modulating the NF-κB pathway in both basic and translational research contexts (detailed review here).

Mechanism of Action of BMS-345541 hydrochloride

BMS-345541 hydrochloride binds to an allosteric site on IKK, distinct from the ATP-binding pocket. This interaction results in potent inhibition of IKK-2 (IC₅₀ = 0.3 μM) and moderate inhibition of IKK-1 (IC₅₀ = 4 μM) in vitro. The compound prevents phosphorylation of IκB, thereby blocking the nuclear translocation of NF-κB and subsequent transcription of target genes including TNFα, IL-1β, IL-6, and IL-8. This effect is both stimulus-specific and reversible, and does not affect unrelated kinases or parallel cell signaling pathways. The selectivity profile of BMS-345541 hydrochloride minimizes off-target effects, making it suitable for precision studies in inflammation and cancer biology (APExBIO).

Evidence & Benchmarks

• BMS-345541 hydrochloride inhibits IKK-2 activity with an IC₅₀ of 0.3 μM and IKK-1 with an IC₅₀ of 4 μM in biochemical kinase assays (APExBIO).
• It selectively blocks IκB phosphorylation and subsequent NF-κB activation, reducing expression of pro-inflammatory cytokines (TNFα, IL-1β, IL-6, IL-8) at both mRNA and protein levels in vitro (Zhao et al., 2025).
• Oral administration in animal models yields 100% bioavailability and robust suppression of TNFα production in inflammatory settings (APExBIO).
• BMS-345541 hydrochloride induces apoptosis and G2/M phase cell cycle arrest in T-ALL cell lines, supporting its use in overcoming chemotherapeutic resistance (Peptone Bacteriological).
• The compound demonstrates no inhibition of non-IKK serine/threonine or tyrosine kinases, confirming high selectivity (SNS-032.com).
• RNA-seq data from anti-inflammatory stent studies reinforce the centrality of NF-κB and cytokine suppression in modulating tissue remodeling and inflammation (Zhao et al., 2025).

Applications, Limits & Misconceptions

BMS-345541 hydrochloride is widely used for:

• Dissecting NF-κB signaling in inflammation research.
• Evaluating pro-inflammatory cytokine inhibition in cell and animal models.
• Investigating apoptosis induction and cell cycle arrest in T-ALL and other cancer models.
• Screening for chemoresistance mechanisms in cancer biology.

For a deeper mechanistic perspective on apoptosis and cell cycle modulation, see this advanced insights article, which extends this summary by exploring RIPK1-regulated cell death intersections.

Common Pitfalls or Misconceptions

• BMS-345541 is not a pan-kinase inhibitor; it does not block unrelated serine/threonine or tyrosine kinases at research doses.
• Not suitable for chronic in vivo administration in all models; long-term safety has not been established beyond acute studies.
• Does not disrupt NF-κB-independent inflammatory cascades; its effects are limited to IKK-dependent signaling.
• Not effective in models where NF-κB activation is bypassed or mutated downstream.
• Solubility is restricted to water; BMS-345541 hydrochloride is insoluble in ethanol and DMSO, limiting its use in certain organic solvent protocols.

Workflow Integration & Parameters

BMS-345541 hydrochloride (SKU A3248, by APExBIO) is supplied as a stable, ready-to-use powder. Prepare aqueous stock solutions at concentrations up to 60 mg/mL. Store bulk powder and aliquots at -20°C; avoid repeated freeze-thaw cycles. Freshly prepared solutions deliver optimal activity; do not store solutions long-term. In vitro, use 0.1–10 μM working concentrations, titrated for cell type and endpoint. For in vivo rodent models, oral administration achieves full bioavailability; dosing should be optimized per protocol (product page). For practical Q&A scenarios regarding cytotoxicity and workflow, see this technical resource, which details user-driven troubleshooting and assay design—this article updates earlier usage notes with current best practices.

Conclusion & Outlook

BMS-345541 hydrochloride remains a reference-standard selective IKK/NF-κB pathway inhibitor, enabling high-fidelity research in inflammation, immune regulation, and cancer biology. Its reproducible selectivity in vitro and in vivo, combined with robust pro-inflammatory cytokine suppression and apoptosis induction, make it indispensable for mechanistic and translational studies. As clinical and preclinical models advance, BMS-345541 hydrochloride's unique profile will continue to inform drug discovery and therapeutic targeting for NF-κB-driven diseases. For product specifications and ordering, visit the official APExBIO product page.